HC Wainwright reaffirmed their buy rating on shares of Processa Pharmaceuticals (NASDAQ:PCSA – Free Report) in a report published on Monday morning, Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock. HC Wainwright also issued estimates for Processa Pharmaceuticals’ Q2 2024 earnings at ($0.98) EPS, Q3 2024 earnings at ($1.02) EPS, […]